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It has been hypothesized that hepatocyte growth factor (HGF) may play an important role in regulating 
the growth of lung epithelium and in the regeneration of the lung as a paracrine or endocrine factor in 
idiopathic pulmonary fibrosis (IPF). Based on this background, serum HGF was measured in 31 IPF 
patients (21 male/l0 female, median age 60 years). Fifteen age-matched normal non-smokers served as 
the control. Hepatocyte growth factor was measured by enzyme-linked immunosorbent assay with 
monoclonal and polyclonal antibodies against human HGF (Otsuka Assay Laboratories, Tokushima, 
Japan). Elastase: a,-proteinase complex was also measured by enzyme-linked immunosorbent assay. No 
patients had significant liver or renal dysfunction. As a result, mean (standard error) serum HGF 
concentration of the patients with IPF was 0.384 (0.022) ng ml- i, which was significantly high compared 
to normal non-smokers [0.213 (0.012) ng ml- ‘, P<O.OOl, 95% confidence interval was between 0.104 and 
0.2381. Serum HGF values correlated strongly with the plasma elastase: ai proteinase inhibitor complex 
(R=0.679, P<O.OOl). Immunohistochemical staining of lung tissue with anti-human neutrophil elastase 
showed scattered immunopositive cells mainly in interstitium. Immunohistochemical staining with 
mouse anti-human HGF antibody showed that HGF was distributed to the lung epithelial cells in IPF 
lung specimens obtained by open lung biopsy. These results suggest that HGF may play an important 
role in the pathogenesis of IPF. 
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Introduction 
In the lung, hepatocyte growth factor (HGF) is syn- 
thesized and secreted by mesenchymal cells, such as 
macrophages, endothelial cells and fibroblasts, and 
controls proliferation and morphogenesis of epithelial 
cells (1). It has recently been revealed that the lung has 
an endocrine function and produces HGF for the 
regeneration of injured tissues or organs (2). Hepato- 
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cyte growth factor also acts as a pulmotrophic factor 
in lung regeneration after acute lung injury (3), and 
is a potential paracrine growth factor for rat alveolar 
type II cells in primary culture (1). Therefore, the 
authors hypothesized that HGF may play an import- 
ant role in regulating the growth of lung epithelium 
and in the regeneration of the lung as a paracrine or 
endocrine factor in idiopathic pulmonary fibrosis 
(IPF). On the other hand, human neutrophil elastase 
is believed to play an important role in the patho- 
genesis of IPF with regard to degrading the lung 
interstitium (4). Based on this background, HGF was 
measured in serum, bronchoalveolar lavage fluid 
(BALF) and elastase: a,-proteinase inhibitor (PI) 
complexes in plasma and BALF in patients with IPF. 
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Methods 
ETHICAL APPROVAL AND METHOD OF 
DIAGNOSIS OF IPF 
The protocols of this study were approved by the 
institutional review board for human studies, and 
informed written consent was obtained from the 
subjects. Serum and plasma samples were obtained 
from 31 patients with IPF. The diagnosis was made 
on clinical, radiological, physiological and histologi- 
cal grounds. The criteria used included: history of 
dyspnoea and cough, fine crackles on physical exami- 
nation, compatible findings on the chest radiograph 
(diffuse basal reticulonodular shadowing), restrictive 
pattern of pulmonary function, and a reduced diffus- 
ing capacity. In addition, no associated connective 
tissue diseases were present nor was there a history of 
occupational exposure or hypersensitivity. Histologi- 
cal confirmation was obtained in all cases (transbron- 
chial biopsy in 16 patients and open lung biopsy in 
15 patients). In all patients, high-resolution com- 
puted radiographic scanning of the lungs (HRCT) 
was performed. 
SUBJECTS 
The study population consisted of 10 women and 21 
men with an average age of 60 years. The 15 normal 
non-smokers, six women and nine men with an aver- 
age age of 55 years, had no history of lung diseases 
and no clinical findings suggesting lung disease. They 
all had normal chest X-rays and their pulmonary 
function test results were within the normal range. Of 
3 1 patients, 13 patients were receiving low-dose corti- 
costeroids, and two patients were receiving low-dose 
corticosteroids as well as oral cyclophosphamide. 
Blood samples with and without EDTA were 
obtained before breakfast. After centrifugation at 
1000 g for 10 min at 4°C the plasma and the serum 
was frozen and stored at - 70°C until use. 
BRONCHOALVEOLAR LAVAGE 
To sample the lower respiratory tract, flexible fibre- 
optic bronchoscopy and bronchoalveolar lavage were 
performed in 15 patients with IPF and 15 normal 
non-smokers. Bronchoalveolar lavage was performed 
by infusing three 50-ml aliquots of sterile saline at the 
site of the anterior segment of the right lower lobe. 
The last two aliquots were saved for evaluation. Cells 
were separated from alveolar lavage fluid by centri- 
fugation (300 g for 10 min). Total cell number and 
cell differential counts were also evaluated. Broncho- 
alveolar lavage fluid was frozen and stored at - 70°C 
until use. 
MEASUREMENT OF ELASTASE: a,-PROTEINASE 
COMPLEX LEVELS IN PLASMA AND BALF 
Elastase:a,-proteinase (PI) complex concentration 
was determined by using an enzyme-A kit purchased 
from Merck (Diagnostica Merck, Darmstadt, 
Germany). Briefly, the plasma samples were added to 
wells coated with sheep anti-neutrophil elastase IgG. 
This antibody does not cross-react with cathepsin G 
or other neutrophil proteinases. After incubation and 
washing, the solid phase-bound elastase:a,-proteinase 
complexes were further incubated with alkaline 
phosphatase-labelled rabbit anti-a,-proteinase IgG. 
After further washes, p-nitrophenylphosphate was 
added to measure the amount of solid phase-bound 
complexes. The assay was calibrated using a standard 
solution of known elastase:a,-proteinase complex 
concentration. The lower detection limit of this assay 
was 3 ng ml - ‘. Data were expressed as mean values 
from duplicate determinations. 
MEASUREMENT OF HGF LEVELS IN SERUM 
AND BALF 
Hepatocyte growth factor was measured by ELISA 
with monoclonal and polyclonal antibodies against 
human HGF (Otsuka Assay Laboratories, 
Tokushima, Japan). This assay was calibrated using a 
standard solution of known HGF concentration. The 
lower detection limit of this assay was 0.02 ng ml - ‘. 
Data were expressed as mean values from duplicate 
determinations. 
IMMUNOSTAINING BY ANTI-NEUTROPHIL 
ELASTASE 
To evaluate the site of neutrophil accumulation in 
patients with IPF, 15 specimens obtained by open 
lung biopsy were immunohistochemically stained 
using anti-human neutrophil elastase (DAKO, M752) 
by the Avidin-Biotin-Peroxidase (ABC) method using 
a DAK0 LSAB kit (DAK0 Japan, Kyoto). Normal 
lung was also stained as a control. 
IMMUNOSTAINING BY ANTI-HGF ANTIBODY 
Immunohistochemical staining with rabbit polyclonal 
anti-human HGF antibody (gift from Toshikazu 
Nakamura) was performed in 15 lung specimens by 
ABC method using a DAK0 LSAB kit. Normal lung 
was also stained as a control. 
STATISTICAL METHODS 
All comparisons between groups were made using 
the non-parametric Wilcoxon-Mann-Whitney rank 
order test. Correlations were evaluated by the 
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FIG. 1. Concentrations of (a) plasma elastase: a,-proteinase and (b) serum hepatocyte growth factor (HGF) 
complex in the study population. IPF, idiopathic pulmonary fibrosis. 
Pearson’s correlation coefficient, and Fisher’s 1’ to z 
method was used to calculate the P values. 
Results 
Figure 1 (a) shows the concentrations of plasma 
elastaseq-proteinase complex in the study popu- 
lation. Data are expressed as means & standard 
error. Plasma elastaseq-proteinase complexes in 
patients with interstitial pneumonia were significantly 
high (539.9 f 77.4 ng ml- ‘) compared with normal 
non-smokers (130.3 f 5.5 ng ml-‘, PcO.01, 95% 
confidence interval was between 183.9 and 635.3). 
Figure 1 (b) shows the concentrations of serum 
HGF in the study population. Data are expressed as 
means f standard error. Serum HGF in patients with 
IPF were significantly high (0.384 + 0.022 ng ml - ‘) 
compared with normal non-smokers (0.213 & 
0.014 ng ml- ‘, PcO.01, 95% confidence interval was 
between 0.104 and 0.238). 
In BALF obtained from 15 patients with IPF, the 
total cell count was 1.85 & 0.23 x lo5 ml- ‘, and 
differential counts of macrophages, lymphocytes, 
neutrophils and eosinophils were 8 1 .O f 6.4%, 
15.3 f 6.1%, 3.0 f 1.1% and 0.7 f 0.4%, respectively. 
Figure 2 (a) shows the concentrations of 
elastase:a,-proteinase complex in BALF in the study 
population. As the mean concentration of total pro- 
tein in BALF in both study groups was almost the 
same, data (means f standard error) were expressed 
as the absolute values. Complexes in BALF in 
patients with IPF were significantly high (213.3 f 
71.6 ng mg - ’ albumin) compared with normal non- 
smokers (8.3 & 2.9 ng mg - ’ albumin, P<O.Ol, 95% 
confidence interval was between 58.3 and 351.8). 
Figure 2 (b) shows the concentrations of HGF in 
BALF in the study population. Data are expressed as 
means f standard error. Hepatocyte growth factor in 
BALF in patients with IPF were significantly high 
(0.09 % 0.03 ng mg-’ albumin) compared with nor- 
mal non-smokers (0.004 f 0.002 ng mg - ’ albumin, 
P~0.01, 95% confidence interval was between 0.025 
and 0.137). The ratio of HGF/albumin in BALF 
divided by serum HGF/serum albumin concentration 
was 12.3 + 3.9. 
Figure 3 (a) shows the correlation between plasma 
elastaseq-proteinase complex values and serum 
HGF values in patients with IPF (~~31). Strong 
correlation was demonstrated (Rz0.679, P<O.OOOl). 
Figure 3 (b) shows the correlation between 
elastaseq-proteinase complex values in BALF 
and HGF values in BALF in patients with IPF 
(n= 15). No significant correlation was demonstrated 
(R=0.197, P=O.4883). 
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FIG. 2. Concentrations of (a) elastase: a,-proteinase and (b) hepatocyte growth factor (HGF) complex in 
bronchoalveolar lavage fluid (BALF) in the study population. IPF, idiopathic pulmonary fibrosis. 
Plate 1 shows the results of immunostain by anti- 
human neutrophil elastase in IPF lung specimens. 
Immunopositive cells were observed mainly in the 
interstitium. Neutrophil elastase stains were detected 
around the fibrosis, as well as the alveolar septa. 
Some immunopositive cells were observed in the 
alveolar space. Strong staining of neutrophils was 
observed along the endothelium in pulmonary 
microvessels in some patients with IPF (figure not 
shown). There were few neutrophils distributed in the 
normal lung. 
Plate 2 shows the results of immunostain by anti- 
HGF antibody. Immunostain by anti-HGF antibody 
was only possible in frozen sections and was im- 
possible in paraffin sections. Immunohistochemical 
staining with rabbit polyclonal anti-human HGF 
antibody showed that HGF was distributed to the 
lung epithelial cells in IPF lung specimens. There was 
no significant staining to the alveolar epithelial cells 
in the normal lung (data not shown). 
Discussion 
Idiopathic pulmonary fibrosis is a disease of un- 
known aetiology that is characterized by the accumu- 
lation of neutrophils and mononuclear cells, followed 
by the progressive deposition of collagen within the 
interstitium and subsequent destruction of lung 
airspace. Significantly, patients with IPF have an 
expected median survival of less than 5 yr (5,6). 
Increases in polymorphonuclear neutrophils in BALF 
and in lung tissue have been demonstrated in patients 
with IPF (7). Excessive neutrophils in BALF have 
been associated with a higher likelihood of disease 
progression and a failure to respond to immuno- 
suppressive therapy (8). Therefore, IPF has been 
considered to be a neutrophilic alveolitis since 
neutrophils may play an important role in the 
pathogenesis of IPF (4). 
Neutrophil elastase, a neutral serine protease, is 
localized to the azurophilic or primary granules in 
neutrophils, and plays an important role in host 
defence (9). It has been reported that the formation 
of the plasma elastase:a,-proteinase complex reflects 
a rapid response of host to infection and is a sensi- 
tive indicator of bacterial infections during and 
beyond the neonatal period (10,ll). In addition, 
sequential determinations of the elastase:a,- 
proteinase complex seem to be helpful in following 
the course of systemic bacterial infections and to 
determine the adequacy of therapy (11,12). In the 
present study, the increase of elastase:a,-proteinase 
complexes in plasma and BALF was demonstrated in 
patients with IPF. 
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FIG. 3. Correlation between (a) plasma elastaseq- 
proteinase PI complex values and serum hepatocyte 
growth factor (HGF) values, and (b) elastaseq- 
proteinase complex values in bronchoalveolar 
lavage fluid (BALF) and HGF values in BALF, in 
patients with idiopathic pulmonary fibrosis. 
In this study, neutrophil elastase was also used as a 
neutrophil marker in immunostain to distinguish 
neutrophils in the lung. It is especially useful in cases 
where many of the infiltrating neutrophils are prema- 
ture (have a non-segmented nucleus). In this study, to 
evaluate the site of neutrophil accumulation in 
patients with IPF, specimens were obtained by open 
lung biopsy and were immunohistochemically stained 
using anti-human neutrophil elastase. Neutrophil 
elastase stains were detected around the fibrosis, as 
well as the alveolar septa. The authors also reported 
recently that strong staining of neutrophils was 
observed along the endothelium in pulmonary micro- 
vessels in some patients with IPF (13). These obser- 
vations suggest that activation of neutrophils at the 
site of pulmonary interstitium takes place in patients 
with IPF. These results suggested that neutrophil 
elastase may play a role in the pathogenesis of IPF. 
PLATE 1. Immunostain by anti-human neutrophil 
elastase in idiopathic pulmonary fibrosis lung 
specimens. Neutrophil elastase stains were detected 
around the honey-combing, as well as the alveolar 
septa. Some immunopositive cells were observed in 
the alveolar space. 
PLATE 2. Immunostain by anti-hepatocyte growth 
factor antibody. Hepatocyte growth factor was 
distributed to the lung epithelial cells in idiopathic 
pulmonary fibrosis lung specimens. 
It has been reported that HGF is a growth factor 
that may mediate human renal cyst formation (14). 
As in renal cyst formation, the process of lung 
remodelling also includes epithelial cell proliferation 
and a remodelling of the extracellular matrix. In the 
lung, HGF is synthesized and secreted by mesenchy- 
ma1 cells, such as macrophages, endothelial cells and 
fibroblasts, and it controls proliferation and morpho- 
genesis of epithelial cells (1). It has recently been 
revealed that the lung has an endocrine function and 
produces HGF for the regeneration of injured tissues 
or organs (2). Hepatocyte growth factor also acts as a 
pulmotrophic factor in lung regeneration after acute 
lung injury (3), and is a potential paracrine growth 
factor for rat alveolar type II cells in primary culture 
(1). In the present study, the increase of HGF in 
serum and BALF was demonstrated in patients with 
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IPF. Therefore, one may hypothesize that this HGF 
may play an important role in regulating the growth 
of the lung epithelium and in the regeneration of the 
lung in IPF. 
The clinical significance of HGF in patients 
with IPF should be considered. Maeda et al. have 
suggested that serum HGF levels increase in inflam- 
matory lung disease including interstitial pneumoni- 
tis, and HGF levels in the surviving patients rapidly 
decrease with treatment (15). The present authors 
also showed previously that plasma HGF concen- 
tration in patients with pneumonia was significantly 
higher when compared to patients without pneumo- 
nia, and the increase of serum HGF followed shortly 
after the onset of inflammation (16). This may suggest 
that HGF is an indicator of lung repair after lung 
damage in patients with pneumonia (16). Although 
the increase of HGF in serum may not be specific to 
IPF, future studies are needed to determine the 
clinical usefulness of measuring and monitoring 
serum HGF in patients with IPF. 
Hepatocyte growth factor is thought to be pro- 
duced by mesenchymal cells. However, immunohisto- 
chemical staining with anti-human HGF antibody 
showed that the HGF was distributed to the lung 
epithelial cells in the IPF lung. Defiances et al. also 
found that HGF is localized in the bronchial epithe- 
lium of developing rats, using an immunohistochemi- 
cal study (17). They also showed that HGF is 
produced by mesenchymal cells in each organ, which 
might regulate epithelial cells growth and morpho- 
genesis (17). Yanagita et al. reported that following 
intratracheal HCl injection, HGF mRNA and HGF 
activity in the lung increased, and the HGF receptor 
on the plasma membranes of the lung was downregu- 
lated, probably due to internalization of the HGF 
receptor following HGF binding (2,18). In the present 
study, the ratio of HGF/albumin in BALF divided by 
serum HGF/serum albumin concentration was 
12,3 & 3.9. Although the source of HGF in alveolus 
was not clear, this evidence suggested that HGF 
might be locally produced in the alveolus. 
In conclusion, these results suggest that serum 
HGF increased in patients with IPF, and significantly 
correlated with the plasma elastase: a,-proteinase 
complex. Hepatocyte growth factor may play an 
important role in the pathogenesis of IPF. 
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